Muscular Dystrophy – Pipeline Review, H2 2011

Muscular Dystrophy – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Muscular Dystrophy - Pipeline Review, H2 2011', provides an overview of the Muscular Dystrophy therapeutic pipeline. This report provides information on the therapeutic development for Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscular Dystrophy. 'Muscular Dystrophy - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Muscular Dystrophy.
• A review of the Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Muscular Dystrophy pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Muscular Dystrophy.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Muscular Dystrophy pipeline depth and focus of Muscular Dystrophy therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Muscular Dystrophy Overview
Therapeutics Development
An Overview of Pipeline Products for Muscular Dystrophy
Muscular Dystrophy Therapeutics under Development by Companies
Muscular Dystrophy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Muscular Dystrophy Therapeutics – Products under Development by Companies
Muscular Dystrophy Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Muscular Dystrophy Therapeutics Development
GlaxoSmithKline plc
AVI BioPharma Inc.
Galapagos NV
Summit Corporation plc
Santhera Pharmaceuticals Holding AG
Amsterdam Molecular Therapeutics BV
The Avicena Group, Inc.
Acceleron Pharma, Inc.
Nobelpharma Co., Ltd.
PTC Therapeutics, Inc.
UMN Pharma Inc.
SanBio, Inc.
Genethon
Prosensa Therapeutics B.V.
Muscular Dystrophy – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ataluren - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
SMT C1100 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
ACE-031 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AVI-4658 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AVI-5038 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
GSK2402968 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
DMD-02 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Omigapil - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PRO044 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AMT-080 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
SB308 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Drug for Myotonic Dystrophy Type 1 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
UMN-03 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
GLPG0492 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Gentamicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Catena - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Sunphenon EGCg - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Increlex - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
NPC-09 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PRO045 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PRO053 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PRO135 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PRO052 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PRO055 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
rAAV1.tMCK.Human-Alpha-Sarcoglycan - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Flavocoxid - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AAV1 Gamma Sarcoglycan Gene Therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mexiletine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Duchenne Muscular Dystrophy Program - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Drug For Duchenne Muscular Dystrophy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
LAM-111 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PRT-300 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PRT-20 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
RE-001 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Muscular Dystrophy Therapeutics – Drug Profile Updates
Muscular Dystrophy Therapeutics – Discontinued Products
Muscular Dystrophy – Product Development Milestones
Featured News & Press Releases
Dec 19, 2011: Summit Secures $1.5m Agreement With US Duchenne Muscular Dystrophy Organizations
Nov 24, 2011: SMT C1100 Receives Orphan Drug Status From FDA For Treatment Of Duchenne Muscular Dystrophy
Oct 19, 2011: Santhera To Present Clinical Data Of Catena In Duchenne Muscular Dystrophy At 2011 Congress Of World Muscle Society
Oct 18, 2011: AVI BioPharma Announces Data Presentation For Eteplirsen At 16th International World Muscle Society Congress
Oct 14, 2011: Action Duchenne Announces Clinical Development Program Update From GSK
Oct 14, 2011: Action Duchenne Announces GSK's Update On Phase II Study Of Muscular Dystrophy Drug
Aug 24, 2011: Santhera Obtains US Patent For Use Of Catena In Treatment Of Muscular Dystrophies
Aug 15, 2011: AVI BioPharma Initiates Dosing In Phase II Study Of Eteplirsen In Duchenne Muscular Dystrophy Patients
Jul 25, 2011: The Lancet Publishes Clinical Trial Data That Demonstrate Statistically Significant And Dose-Dependent Expression Of Dystrophin In Duchenne Muscular Dystrophy Patients Treated With AVI BioPharma's Eteplirsen
Jun 09, 2011: AVI BioPharma Provides Update On Initiation Of Eteplirsen Phase II Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Muscular Dystrophy, H2 2011
Products under Development for Muscular Dystrophy – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
GlaxoSmithKline plc, H2 2011
AVI BioPharma Inc., H2 2011
Galapagos NV, H2 2011
Summit Corporation plc, H2 2011
Santhera Pharmaceuticals Holding AG, H2 2011
Amsterdam Molecular Therapeutics BV, H2 2011
The Avicena Group, Inc., H2 2011
Acceleron Pharma, Inc., H2 2011
Nobelpharma Co., Ltd., H2 2011
PTC Therapeutics, Inc., H2 2011
UMN Pharma Inc., H2 2011
SanBio, Inc., H2 2011
Genethon, H2 2011
Prosensa Therapeutics B.V., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Muscular Dystrophy Therapeutics – Drug Profile Updates
Muscular Dystrophy Therapeutics – Discontinued Products

LIST OF FIGURES

Number of Products under Development for Muscular Dystrophy, H2 2011
Products under Development for Muscular Dystrophy – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top